Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
  1. Homepage
  2. Equities
  3. China
  4. Shanghai Stock Exchange
  5. Shanghai Fosun Pharmaceutical (Group) Co., Ltd.
  6. News
  7. Summary
    600196   CNE000000X38

SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.

(600196)
  Report
SummaryChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
SummaryMost relevantAll NewsAnalyst Reco.Other languagesPress ReleasesOfficial PublicationsSector news

Shanghai Fosun Pharmaceutical's H-Shares Surge to All-Time High

05/03/2021 | 04:32am EST

By Clarence Leong

Shanghai Fosun Pharmaceutical (Group) Co.'s Hong Kong-listed shares soared as much as 20% on Monday, touching an all-time high of HK$59.45.

The surge mirrored its A-shares, which jumped 10% on both Wednesday and Friday, following its first-quarter results.

The company's first-quarter operating income advanced 37% from a year earlier to 8.06 billion yuan ($1.24 billion), while net profit rose 47% to CNY847.2 million, thanks to growth in drug sales, as well as a low-base effect as the company was hit by the Covid-19 pandemic last year.

Its A-shares last traded at CNY60.24, outperforming its peers with a 51% gain for the month of April. In contrast, Jiangsu Hengrui Medicine Co.'s share price fell 8.7% last month, while Guangzhou Baiyunshan Pharmaceutical Holdings Co. rose 10%. The mainland China market was closed Monday for a holiday.

Bocom International said the results were in line with its expectations, and that the company's pharmaceutical segment could maintain a double-digit compound annual growth rate, partly thanks to the expanded hospital sales channel for innovative drugs.

The company distributes the Covid-19 vaccines developed by BioNTech SE in the Greater China region.

Its shares were most recently up 19.45% at HK$58.95.

Write to Clarence Leong at clarence.leong@wsj.com

(END) Dow Jones Newswires

05-03-21 0431ET

Stocks mentioned in the article
ChangeLast1st jan.
BIONTECH SE 8.17% 302.69 Delayed Quote.310.30%
DJ INDUSTRIAL 1.40% 35719.43 Delayed Quote.13.18%
GUANGZHOU BAIYUNSHAN PHARMACEUTICAL HOLDINGS COMPANY LIMITED 0.64% 18.92 End-of-day quote.-0.53%
JIANGSU HENGRUI MEDICINE CO., LTD. 1.83% 50.18 End-of-day quote.-45.98%
SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD. 0.21% 51.33 End-of-day quote.-4.93%
UNITED STATES DOLLAR (B) / CHINESE YUAN IN HONG KONG (USD/CNH) -0.17% 6.3623 Delayed Quote.-1.92%
All news about SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
08:22aSHANGHAI FOSUN PHARMACEUTICAL : Poll results of the resolutions proposed at the 2021 third..
PU
08:02aSHANGHAI FOSUN PHARMACEUTICAL : List of directors and their roles and function
PU
12/02SHANGHAI FOSUN PHARMACEUTICAL : Overseas regulatory announcement (h shares)
PU
12/01SHANGHAI FOSUN PHARMACEUTICAL : Monthly return of equity issuer on movements in securities..
PU
12/01SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement - lapse of implementation period of..
PU
11/26SoftBank in investment talks with Chinese mRNA vaccine firm Abogen - sources
RE
11/26SHANGHAI FOSUN PHARMACEUTICAL : Overseas regulatory announcement (h shares)
PU
11/25Fosun Pharma Forms Two Funds to Invest in New Drug-Related Projects
MT
11/24SHANGHAI FOSUN PHARMACEUTICAL : Voluntary announcement regarding the establishment of inve..
PU
11/24SHANGHAI FOSUN PHARMACEUTICAL : Connected transaction formation of partnership
PU
More news
Analyst Recommendations on SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
More recommendations
Financials
Sales 2021 36 295 M 5 702 M 5 702 M
Net income 2021 4 480 M 704 M 704 M
Net Debt 2021 14 452 M 2 270 M 2 270 M
P/E ratio 2021 29,7x
Yield 2021 0,89%
Capitalization 119 B 18 763 M 18 768 M
EV / Sales 2021 3,69x
EV / Sales 2022 3,06x
Nbr of Employees 32 258
Free-Float 58,1%
Chart SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Duration : Period :
Shanghai Fosun Pharmaceutical (Group) Co., Ltd. Technical Analysis Chart | 600196 | CNE000000X38 | MarketScreener
Technical analysis trends SHANGHAI FOSUN PHARMACEUTICAL (GROUP) CO., LTD.
Short TermMid-TermLong Term
TrendsNeutralBearishNeutral
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus OUTPERFORM
Number of Analysts 11
Last Close Price 51,33 CNY
Average target price 68,65 CNY
Spread / Average Target 33,7%
EPS Revisions
Managers and Directors
Xiao Hui Guan Executive President & Chief Financial Officer
Yu Qing Chen Co-President
Ke Xin Wang Co-President
Dong Ming Li Co-President
Yi Fang Wu Chairman